CAR-T cell therapy for advanced melanoma using NG2 and DLL3 targets
Part of Cancer, Skin clinical trials.
This trial tests a new treatment using your own immune cells (CAR-T cells) that are modified to find and attack melanoma cells with specific markers called NG2 and DLL3. It is for people whose melanoma has spread or come back after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your melanoma must have the NG2 and DLL3 markers, as shown by a lab test.
- You must be between 18 and 75 years old.
- You must weigh at least 40 kg (about 88 pounds).
- Your cancer must have progressed or returned after at least one standard treatment.
- You must be in fairly good health, with normal heart, lung, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a new treatment for advanced melanoma that can be surgically removed. It combines your own immune cells (called gamma-delta T cells) with a drug (interferon or a PD-1 blocker) to see if it helps the body fight the cancer before and after surgery.
This trial tests engineered immune cells (CAR-NK cells) designed to target two markers found on melanoma cells. The goal is to help patients with melanoma that has spread or cannot be surgically removed and has not responded to or is unsuitable for standard treatments.
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.